Valuation: Cantargia AB

Market Cap 416M 41.99M 37.67M 34.83M 31.54M 58.93M 4B 59.64M 166M 2.09B 158M 154M 6.64B P/E 2026 *
-2.34x
P/E 2027 * -2.31x
Enterprise Value 416M 41.99M 37.67M 34.83M 31.54M 58.93M 4B 59.64M 166M 2.09B 158M 154M 6.64B EV / Sales 2026 *
1,041x
EV / Sales 2027 * 11.6x
Free-Float
97.06%
Yield 2026 *
-
Yield 2027 * -
1 day+12.59%
1 week+19.49%
Current month+7.02%
1 month+15.84%
3 months-11.84%
6 months-56.65%
Current year-61.03%
1 week 1.34
Extreme 1.342
1.74
1 month 1.25
Extreme 1.25
1.79
Current year 1.25
Extreme 1.25
6.59
1 year 1.25
Extreme 1.25
6.59
3 years 1
Extreme 1
6.59
5 years 1
Extreme 1
21.66
10 years 1
Extreme 1
71.8
Manager TitleAgeSince
Chief Executive Officer 60 31/08/2025
Director of Finance/CFO 56 14/06/2023
Chief Tech/Sci/R&D Officer - 25/10/2026
Director TitleAgeSince
Chairman 66 31/12/2015
Director/Board Member 55 31/12/2017
Director/Board Member 66 30/09/2020
Date Insider Type Main position Quantity % Market Cap. Importance
22/06/26 Buy

Chief Technology Officer

18,238 0.0073%
22/06/26 Exercice

Director

-74,997 0.0302%
02/04/26 Free

Chief Technology Officer

80,000 0.0322%
Change 5-day change 1-year change 3-year change Capi.($)
+12.59%+19.49%-53.33%-53.24% 41.99M
+0.34%-3.03%+37.45%+61.06% 64.14B
+0.93%+2.76%+12.34%+84.04% 55.53B
+1.06%+1.40%+12.62%+104.49% 53.03B
-1.27%-1.11%+26.36%+55.36% 45.99B
+0.20%-2.04%+18.94%+100.67% 42.45B
+0.46%+1.75%+229.16%+940.76% 40.45B
+0.64%-3.95%+11.15%+45.57% 32.25B
-1.89%+43.59%+105.00%+91.41% 34.47B
-2.72%-0.44%+23.18%-10.77% 24.23B
Average +1.05%+4.37%+42.29%+141.94% 39.26B
Weighted average by Cap. -0.01%+3.16%+49.88%+161.38%

Financials

2026 *2027 *
Net sales 400K 40.33K 36.19K 33.46K 30.3K 56.61K 3.84M 57.29K 159K 2.01M 151K 148K 6.38M 36.05M 3.63M 3.26M 3.02M 2.73M 5.1M 346M 5.16M 14.36M 181M 13.64M 13.35M 575M
Net income -159M -15.99M -14.34M -13.26M -12.01M -22.44M -1.52B -22.71M -63.15M -797M -59.99M -58.72M -2.53B -151M -15.18M -13.62M -12.59M -11.4M -21.31M -1.45B -21.56M -59.96M -757M -56.96M -55.76M -2.4B
Net Debt - -
Projected Income Statement - Annual - Cantargia AB
Logo Cantargia AB
Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
Employees
22
Date Price Change Volume
29/10/26 SEK 1.631 +10.43% 5,681,947
28/10/26 SEK 1.477 +7.50% 1,381,219
27/10/26 SEK 1.374 -0.72% 1,124,075
26/10/26 SEK 1.384 0.00% 1,783,737
23/10/26 SEK 1.384 +1.39% 838,582
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cantargia AB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.477SEK
Average target price
8.250SEK
Spread / Average Target
+458.56%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cantargia AB
  1. Stock Market
  2. Stocks
  3. CANTA Stock